PracticeUpdate Oncology May 2019

BREAK THE CYCLE With the first PBS listed CDK4/6 inhibitor - from 1 st July 1,2 PROVEN EFFICACY THAT REDEFINES FIRST LINE 1,2 KISQALI is a CDK4/6 inhibitor used in combination with an aromatase inhibitor for FIRST-LINE HR+/HER2- advanced/metastatic breast cancer 1

THE FIRST PBS LISTED CDK4/6 INHIBITOR

PBS Information: Authority Required. Refer to the PBS Schedule for full Authority information.

PLEASEREVIEWPRODUCT INFORMATIONBEFOREPRESCRIBING. APPROVEDPRODUCT INFORMATION IS AVAILABLE ONLINE AT WWW.NOVARTIS.COM.AU/PRODUCTS/HEALTHCARE-PROFESSIONALS. SHTML OR WWW.EBS.TGA.GOV.AU Kisqali ® (ribociclib): Indication: In combination with an aromatase inhibitor, for the treatment of men and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer, as an initial endocrine therapy. Contraindications: QTcF>450ms; hypersensitivity to active substance, ingredients, soy products. Precautions: ECG, CBC, serumelectrolytes, LFTs, and pregnancy statusmust be assessed prior to initiation of treatment. QT interval prolongation, hepatobiliary toxicity, neutropenia (including febrile). Monitoring during treatment – see full PI. Pregnancy (Category D), effective contraception, lactation, fertility. Interactions: Strong CYP3A inhibitors or inducers. Caution with narrow therapeutic index CYP3A substrates. Monitor for ADRs. Avoid co-administration with drugs that have a potential to prolong the QT interval. Avoid pomegranate, grapefruit. Adverse effects: Very common (≥10%):